 Brian Stauffer
Concepts (453)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 12 | 2023 | 1051 | 2.780 |
Why?
| | Endothelium, Vascular | 34 | 2023 | 829 | 2.630 |
Why?
| | Cardiomyopathy, Dilated | 12 | 2021 | 348 | 1.880 |
Why?
| | Endothelin-1 | 14 | 2023 | 165 | 1.860 |
Why?
| | Vasodilation | 23 | 2023 | 414 | 1.750 |
Why?
| | Heart Ventricles | 11 | 2021 | 710 | 1.470 |
Why?
| | Metoprolol | 2 | 2022 | 37 | 1.350 |
Why?
| | Vasoconstriction | 12 | 2023 | 174 | 1.280 |
Why?
| | Fibrinolysis | 9 | 2023 | 126 | 1.280 |
Why?
| | Myocytes, Cardiac | 9 | 2023 | 447 | 1.270 |
Why?
| | Myocardium | 11 | 2017 | 906 | 1.140 |
Why?
| | Blood Pressure | 12 | 2022 | 1521 | 1.080 |
Why?
| | Obesity | 19 | 2023 | 2501 | 1.070 |
Why?
| | Receptors, Adrenergic, beta | 3 | 2016 | 126 | 1.030 |
Why?
| | Heart Failure | 10 | 2023 | 1955 | 0.960 |
Why?
| | MicroRNAs | 10 | 2021 | 598 | 0.920 |
Why?
| | Nebivolol | 3 | 2022 | 9 | 0.910 |
Why?
| | Exercise | 12 | 2023 | 1617 | 0.890 |
Why?
| | Vasodilator Agents | 18 | 2023 | 303 | 0.850 |
Why?
| | Overweight | 9 | 2019 | 473 | 0.830 |
Why?
| | Postmenopause | 8 | 2023 | 301 | 0.830 |
Why?
| | Qigong | 1 | 2022 | 1 | 0.790 |
Why?
| | Isoproterenol | 4 | 2018 | 105 | 0.770 |
Why?
| | Forearm | 15 | 2021 | 111 | 0.750 |
Why?
| | C-Reactive Protein | 6 | 2015 | 360 | 0.740 |
Why?
| | Resistance Training | 1 | 2023 | 113 | 0.730 |
Why?
| | Male | 85 | 2023 | 55112 | 0.710 |
Why?
| | Aging | 13 | 2022 | 1601 | 0.710 |
Why?
| | Nitric Oxide | 8 | 2023 | 814 | 0.690 |
Why?
| | Middle Aged | 68 | 2023 | 26552 | 0.680 |
Why?
| | Sleep Deprivation | 5 | 2021 | 157 | 0.660 |
Why?
| | Tissue Plasminogen Activator | 10 | 2023 | 204 | 0.650 |
Why?
| | Mendelian Randomization Analysis | 1 | 2019 | 43 | 0.640 |
Why?
| | Cell-Derived Microparticles | 4 | 2023 | 54 | 0.640 |
Why?
| | Troponin I | 1 | 2019 | 67 | 0.640 |
Why?
| | Mitochondria, Heart | 3 | 2020 | 72 | 0.620 |
Why?
| | Meta-Analysis as Topic | 1 | 2019 | 155 | 0.620 |
Why?
| | Heart Diseases | 3 | 2013 | 327 | 0.610 |
Why?
| | Humans | 101 | 2023 | 113531 | 0.610 |
Why?
| | Coronary Disease | 2 | 2019 | 347 | 0.610 |
Why?
| | Cardiolipins | 2 | 2020 | 70 | 0.600 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 427 | 0.600 |
Why?
| | Female | 73 | 2023 | 59115 | 0.600 |
Why?
| | Calcium | 4 | 2021 | 1086 | 0.590 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 469 | 0.580 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 2 | 2017 | 9 | 0.580 |
Why?
| | Regional Blood Flow | 18 | 2023 | 407 | 0.570 |
Why?
| | Rest | 3 | 2022 | 97 | 0.560 |
Why?
| | Death, Sudden, Cardiac | 1 | 2018 | 160 | 0.560 |
Why?
| | Vasoconstrictor Agents | 6 | 2023 | 113 | 0.550 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 1205 | 0.550 |
Why?
| | G-Protein-Coupled Receptor Kinase 2 | 1 | 2016 | 11 | 0.550 |
Why?
| | Shock, Cardiogenic | 1 | 2017 | 54 | 0.540 |
Why?
| | Heart Arrest | 1 | 2020 | 293 | 0.530 |
Why?
| | Sex Characteristics | 6 | 2017 | 633 | 0.530 |
Why?
| | Epoprostenol | 1 | 2017 | 132 | 0.520 |
Why?
| | Arrhythmias, Cardiac | 1 | 2018 | 281 | 0.520 |
Why?
| | Heart Rate | 2 | 2022 | 705 | 0.510 |
Why?
| | Endothelial Cells | 7 | 2020 | 677 | 0.500 |
Why?
| | Cardiovascular Diseases | 9 | 2022 | 1725 | 0.500 |
Why?
| | Myocardial Infarction | 2 | 2017 | 932 | 0.490 |
Why?
| | YY1 Transcription Factor | 1 | 2015 | 27 | 0.490 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 333 | 0.490 |
Why?
| | Coronavirus Infections | 1 | 2020 | 325 | 0.480 |
Why?
| | Ventricular Dysfunction, Right | 2 | 2017 | 216 | 0.480 |
Why?
| | Phosphorylation | 6 | 2021 | 1537 | 0.470 |
Why?
| | Cardiomegaly | 1 | 2015 | 158 | 0.450 |
Why?
| | Adult | 40 | 2023 | 30245 | 0.450 |
Why?
| | Circulating MicroRNA | 3 | 2019 | 24 | 0.450 |
Why?
| | Muscle Tonus | 2 | 2010 | 17 | 0.420 |
Why?
| | Acetylcholine | 14 | 2023 | 163 | 0.420 |
Why?
| | Muscle, Smooth, Vascular | 4 | 2010 | 407 | 0.420 |
Why?
| | Transcriptome | 2 | 2021 | 719 | 0.420 |
Why?
| | Sleep | 5 | 2021 | 568 | 0.410 |
Why?
| | Connexin 43 | 2 | 2012 | 23 | 0.400 |
Why?
| | Gene Expression Regulation | 5 | 2016 | 2293 | 0.400 |
Why?
| | Pandemics | 1 | 2020 | 1308 | 0.390 |
Why?
| | Peptides, Cyclic | 7 | 2013 | 252 | 0.390 |
Why?
| | Aged | 33 | 2023 | 18944 | 0.390 |
Why?
| | Heart-Assist Devices | 2 | 2016 | 493 | 0.380 |
Why?
| | Heart | 6 | 2021 | 609 | 0.380 |
Why?
| | Atherosclerosis | 2 | 2019 | 342 | 0.370 |
Why?
| | Stroke | 1 | 2019 | 1016 | 0.360 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 46 | 0.360 |
Why?
| | Age Factors | 10 | 2018 | 2875 | 0.350 |
Why?
| | Body Composition | 7 | 2023 | 584 | 0.340 |
Why?
| | Health | 1 | 2010 | 73 | 0.330 |
Why?
| | Ventricular Remodeling | 3 | 2021 | 221 | 0.330 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 53 | 0.330 |
Why?
| | Disease | 1 | 2010 | 85 | 0.330 |
Why?
| | Child, Preschool | 13 | 2021 | 9093 | 0.320 |
Why?
| | beta 2-Microglobulin | 1 | 2008 | 44 | 0.310 |
Why?
| | Testosterone | 2 | 2022 | 341 | 0.310 |
Why?
| | Physical Endurance | 3 | 2013 | 228 | 0.310 |
Why?
| | Metabolic Syndrome | 4 | 2016 | 317 | 0.300 |
Why?
| | Heart Defects, Congenital | 3 | 2021 | 670 | 0.300 |
Why?
| | Child | 19 | 2021 | 18340 | 0.300 |
Why?
| | Prehypertension | 3 | 2014 | 24 | 0.300 |
Why?
| | Gender Identity | 2 | 2006 | 100 | 0.300 |
Why?
| | Nitroprusside | 12 | 2016 | 64 | 0.290 |
Why?
| | Soybean Proteins | 2 | 2014 | 10 | 0.290 |
Why?
| | RNA, Messenger | 7 | 2021 | 2507 | 0.280 |
Why?
| | Estrogen Replacement Therapy | 3 | 2013 | 116 | 0.280 |
Why?
| | Biomarkers | 10 | 2023 | 3389 | 0.270 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 515 | 0.260 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2088 | 0.260 |
Why?
| | Reference Values | 4 | 2016 | 735 | 0.260 |
Why?
| | Hypoplastic Left Heart Syndrome | 3 | 2017 | 102 | 0.250 |
Why?
| | Phosphoric Diester Hydrolases | 2 | 2016 | 44 | 0.250 |
Why?
| | Disease Models, Animal | 4 | 2018 | 3470 | 0.230 |
Why?
| | Phosphodiesterase Inhibitors | 2 | 2016 | 81 | 0.230 |
Why?
| | Genomics | 1 | 2008 | 625 | 0.230 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2017 | 1822 | 0.230 |
Why?
| | Cells, Cultured | 5 | 2019 | 3802 | 0.220 |
Why?
| | Adaptation, Physiological | 3 | 2014 | 465 | 0.210 |
Why?
| | Analysis of Variance | 6 | 2016 | 1208 | 0.210 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 79 | 0.210 |
Why?
| | Proteomics | 1 | 2008 | 808 | 0.210 |
Why?
| | Endothelin Receptor Antagonists | 4 | 2011 | 58 | 0.210 |
Why?
| | Infusions, Intra-Arterial | 5 | 2013 | 46 | 0.200 |
Why?
| | Dietary Fats | 2 | 2015 | 286 | 0.200 |
Why?
| | Apoptosis | 6 | 2023 | 2288 | 0.200 |
Why?
| | Cell Movement | 4 | 2014 | 852 | 0.200 |
Why?
| | Body Weight | 3 | 2023 | 853 | 0.200 |
Why?
| | Physical Fitness | 1 | 2003 | 178 | 0.200 |
Why?
| | Systole | 2 | 2021 | 173 | 0.190 |
Why?
| | Hemodynamics | 2 | 2021 | 996 | 0.190 |
Why?
| | Baroreflex | 1 | 2022 | 54 | 0.190 |
Why?
| | Calcium-Binding Proteins | 2 | 2021 | 201 | 0.190 |
Why?
| | Animals | 15 | 2021 | 31162 | 0.190 |
Why?
| | Plethysmography | 6 | 2022 | 103 | 0.190 |
Why?
| | Focal Adhesions | 1 | 2021 | 42 | 0.190 |
Why?
| | Myocardial Contraction | 3 | 2019 | 314 | 0.190 |
Why?
| | Electrocardiography, Ambulatory | 1 | 2021 | 53 | 0.190 |
Why?
| | Case-Control Studies | 10 | 2018 | 2993 | 0.180 |
Why?
| | Vascular Diseases | 1 | 2023 | 231 | 0.180 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2011 | 57 | 0.180 |
Why?
| | Vasomotor System | 1 | 2021 | 38 | 0.180 |
Why?
| | Spinal Cord Injuries | 1 | 2023 | 171 | 0.180 |
Why?
| | Milrinone | 1 | 2021 | 29 | 0.180 |
Why?
| | Estrogens | 3 | 2012 | 311 | 0.180 |
Why?
| | Serum | 2 | 2018 | 57 | 0.180 |
Why?
| | Cross-Sectional Studies | 12 | 2023 | 4400 | 0.180 |
Why?
| | Hyperemia | 1 | 2020 | 42 | 0.170 |
Why?
| | Time Factors | 7 | 2021 | 6032 | 0.170 |
Why?
| | Heart Transplantation | 3 | 2015 | 652 | 0.170 |
Why?
| | Stem Cells | 3 | 2010 | 538 | 0.170 |
Why?
| | Point-of-Care Systems | 1 | 2021 | 130 | 0.170 |
Why?
| | Inflammation Mediators | 2 | 2018 | 469 | 0.170 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2022 | 286 | 0.170 |
Why?
| | Endothelin A Receptor Antagonists | 4 | 2014 | 24 | 0.160 |
Why?
| | Telomere | 3 | 2010 | 202 | 0.160 |
Why?
| | Physical Exertion | 2 | 2014 | 200 | 0.160 |
Why?
| | Adenylyl Cyclases | 2 | 2016 | 82 | 0.160 |
Why?
| | Adolescent | 8 | 2022 | 17724 | 0.160 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 383 | 0.150 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 22 | 0.150 |
Why?
| | Flecainide | 1 | 2018 | 7 | 0.150 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 94 | 0.150 |
Why?
| | Endothelium | 3 | 2020 | 109 | 0.150 |
Why?
| | Guinea Pigs | 1 | 2018 | 135 | 0.150 |
Why?
| | Walking | 1 | 2022 | 421 | 0.150 |
Why?
| | Up-Regulation | 3 | 2018 | 794 | 0.150 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 2018 | 59 | 0.150 |
Why?
| | Extracellular Matrix | 1 | 2021 | 433 | 0.150 |
Why?
| | Body Mass Index | 7 | 2017 | 1952 | 0.150 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2018 | 106 | 0.150 |
Why?
| | HIV | 1 | 2019 | 205 | 0.140 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2011 | 121 | 0.140 |
Why?
| | Down-Regulation | 2 | 2017 | 593 | 0.140 |
Why?
| | Fibrosis | 5 | 2023 | 452 | 0.140 |
Why?
| | Double-Blind Method | 3 | 2017 | 1643 | 0.140 |
Why?
| | Behavior Therapy | 1 | 2019 | 225 | 0.140 |
Why?
| | Prognosis | 6 | 2018 | 3318 | 0.140 |
Why?
| | Infant | 6 | 2017 | 7922 | 0.140 |
Why?
| | Blood Flow Velocity | 4 | 2022 | 374 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 246 | 0.140 |
Why?
| | Kearns-Sayre Syndrome | 1 | 2016 | 1 | 0.140 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 28 | 0.140 |
Why?
| | Mitochondrial Myopathies | 1 | 2016 | 4 | 0.140 |
Why?
| | Coronary Occlusion | 1 | 2017 | 18 | 0.140 |
Why?
| | Blotting, Western | 2 | 2016 | 1128 | 0.140 |
Why?
| | Treatment Outcome | 3 | 2020 | 9006 | 0.140 |
Why?
| | Atrial Natriuretic Factor | 1 | 2016 | 53 | 0.140 |
Why?
| | Caspase 3 | 4 | 2011 | 227 | 0.140 |
Why?
| | Receptor, Endothelin A | 2 | 2014 | 60 | 0.140 |
Why?
| | Sampling Studies | 1 | 2016 | 90 | 0.130 |
Why?
| | Oxidation-Reduction | 2 | 2018 | 912 | 0.130 |
Why?
| | Specimen Handling | 1 | 2018 | 152 | 0.130 |
Why?
| | Weight Loss | 2 | 2019 | 640 | 0.130 |
Why?
| | Oxidative Stress | 4 | 2022 | 1065 | 0.130 |
Why?
| | Cardiac Catheterization | 1 | 2020 | 540 | 0.130 |
Why?
| | Ventricular Function, Right | 1 | 2018 | 251 | 0.130 |
Why?
| | Bradykinin | 6 | 2008 | 41 | 0.130 |
Why?
| | Plasma | 1 | 2018 | 180 | 0.130 |
Why?
| | Nitric Oxide Synthase Type III | 3 | 2023 | 181 | 0.130 |
Why?
| | Mice | 8 | 2015 | 14679 | 0.130 |
Why?
| | Diet | 2 | 2014 | 1076 | 0.130 |
Why?
| | Rats | 4 | 2021 | 4829 | 0.130 |
Why?
| | Exosomes | 1 | 2017 | 92 | 0.130 |
Why?
| | Carrier Proteins | 1 | 2019 | 685 | 0.130 |
Why?
| | Nitric Oxide Synthase | 4 | 2017 | 209 | 0.130 |
Why?
| | Action Potentials | 1 | 2018 | 402 | 0.120 |
Why?
| | Collagen Type III | 1 | 2015 | 15 | 0.120 |
Why?
| | Administration, Inhalation | 1 | 2017 | 633 | 0.120 |
Why?
| | Blood Pressure Determination | 2 | 2016 | 122 | 0.120 |
Why?
| | Lipids | 3 | 2009 | 558 | 0.120 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 26 | 0.120 |
Why?
| | Phosphodiesterase 3 Inhibitors | 1 | 2014 | 14 | 0.120 |
Why?
| | Ascorbic Acid | 2 | 2021 | 110 | 0.120 |
Why?
| | Cytoskeletal Proteins | 1 | 2015 | 133 | 0.120 |
Why?
| | Tissue Donors | 1 | 2016 | 313 | 0.120 |
Why?
| | Linear Models | 1 | 2016 | 767 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2015 | 125 | 0.110 |
Why?
| | Gene Expression | 3 | 2017 | 1397 | 0.110 |
Why?
| | Young Adult | 10 | 2023 | 10400 | 0.110 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1682 | 0.110 |
Why?
| | Myosin Heavy Chains | 4 | 2014 | 159 | 0.110 |
Why?
| | Receptor, Endothelin B | 2 | 2014 | 51 | 0.110 |
Why?
| | Endothelial Progenitor Cells | 1 | 2014 | 17 | 0.110 |
Why?
| | Diet, High-Fat | 1 | 2015 | 224 | 0.110 |
Why?
| | Adiposity | 3 | 2016 | 458 | 0.110 |
Why?
| | Blood Glucose | 4 | 2013 | 1823 | 0.110 |
Why?
| | Interleukin-6 | 4 | 2022 | 661 | 0.100 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 660 | 0.100 |
Why?
| | Animals, Newborn | 3 | 2021 | 769 | 0.100 |
Why?
| | Phytoestrogens | 1 | 2012 | 13 | 0.100 |
Why?
| | Blood Vessels | 1 | 2014 | 179 | 0.100 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2012 | 39 | 0.100 |
Why?
| | Mitochondrial Proteins | 1 | 2014 | 212 | 0.100 |
Why?
| | Piperidines | 2 | 2013 | 159 | 0.100 |
Why?
| | Cytokines | 2 | 2010 | 1795 | 0.100 |
Why?
| | Oligopeptides | 2 | 2013 | 231 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4384 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 105 | 0.100 |
Why?
| | Signal Transduction | 6 | 2016 | 4439 | 0.100 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2017 | 445 | 0.100 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2023 | 75 | 0.100 |
Why?
| | Glucose Intolerance | 1 | 2013 | 136 | 0.100 |
Why?
| | Mice, Transgenic | 2 | 2015 | 1925 | 0.100 |
Why?
| | Fatty Acids | 1 | 2014 | 380 | 0.090 |
Why?
| | Risk Factors | 9 | 2018 | 8606 | 0.090 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 310 | 0.090 |
Why?
| | Recovery of Function | 1 | 2015 | 567 | 0.090 |
Why?
| | Abdominal Fat | 1 | 2011 | 39 | 0.090 |
Why?
| | Risk Assessment | 2 | 2016 | 2953 | 0.090 |
Why?
| | Organ Specificity | 1 | 2011 | 262 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2013 | 739 | 0.090 |
Why?
| | Estradiol | 1 | 2013 | 450 | 0.090 |
Why?
| | RNA | 1 | 2016 | 801 | 0.090 |
Why?
| | Dyslipidemias | 1 | 2012 | 153 | 0.090 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 306 | 0.090 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2139 | 0.080 |
Why?
| | Chemotaxis | 1 | 2010 | 128 | 0.080 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 223 | 0.080 |
Why?
| | NF-kappa B | 2 | 2023 | 615 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 570 | 0.080 |
Why?
| | Enzyme Inhibitors | 4 | 2017 | 737 | 0.080 |
Why?
| | Norepinephrine | 1 | 2009 | 197 | 0.080 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 94 | 0.080 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.080 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2008 | 21 | 0.080 |
Why?
| | Metalloendopeptidases | 1 | 2008 | 54 | 0.080 |
Why?
| | United States | 3 | 2020 | 12137 | 0.080 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 337 | 0.080 |
Why?
| | Muscarinic Agonists | 1 | 2008 | 9 | 0.070 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2021 | 37 | 0.070 |
Why?
| | Vascular Stiffness | 1 | 2012 | 403 | 0.070 |
Why?
| | Calcium Channel Blockers | 1 | 2008 | 112 | 0.070 |
Why?
| | Infant, Newborn | 2 | 2017 | 5032 | 0.070 |
Why?
| | Physical Conditioning, Animal | 2 | 2006 | 187 | 0.070 |
Why?
| | Substance P | 2 | 2008 | 44 | 0.070 |
Why?
| | Adult Stem Cells | 1 | 2006 | 32 | 0.070 |
Why?
| | Bone Density | 1 | 2010 | 432 | 0.070 |
Why?
| | Retrospective Studies | 2 | 2022 | 12504 | 0.070 |
Why?
| | Flow Cytometry | 3 | 2019 | 1065 | 0.070 |
Why?
| | Hypertrophy | 2 | 2023 | 106 | 0.070 |
Why?
| | Brachial Artery | 2 | 2020 | 173 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1510 | 0.070 |
Why?
| | DNA Methylation | 1 | 2010 | 493 | 0.060 |
Why?
| | Dinucleotide Repeats | 1 | 2005 | 4 | 0.060 |
Why?
| | Colony-Forming Units Assay | 3 | 2014 | 87 | 0.060 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 237 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2440 | 0.060 |
Why?
| | Organ Size | 1 | 2006 | 420 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2014 | 496 | 0.060 |
Why?
| | Triglycerides | 2 | 2005 | 464 | 0.060 |
Why?
| | Estrogen Receptor alpha | 1 | 2005 | 121 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 371 | 0.060 |
Why?
| | Diacetyl | 1 | 2003 | 7 | 0.060 |
Why?
| | Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.060 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2003 | 16 | 0.060 |
Why?
| | Quadriplegia | 1 | 2023 | 12 | 0.060 |
Why?
| | von Willebrand Factor | 1 | 2023 | 55 | 0.050 |
Why?
| | Induced Pluripotent Stem Cells | 2 | 2017 | 182 | 0.050 |
Why?
| | Sex Factors | 3 | 2014 | 1705 | 0.050 |
Why?
| | Thrombophilia | 1 | 2023 | 61 | 0.050 |
Why?
| | Actinin | 1 | 2023 | 13 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2023 | 87 | 0.050 |
Why?
| | Inflammation | 2 | 2019 | 2444 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2010 | 1725 | 0.050 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 33 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1282 | 0.050 |
Why?
| | Fenofibrate | 1 | 2003 | 24 | 0.050 |
Why?
| | Troponin T | 1 | 2023 | 49 | 0.050 |
Why?
| | Calcium Signaling | 1 | 2004 | 210 | 0.050 |
Why?
| | Cyclic AMP | 2 | 2014 | 222 | 0.050 |
Why?
| | Endopeptidase K | 1 | 2021 | 14 | 0.050 |
Why?
| | Ribonucleases | 1 | 2021 | 52 | 0.050 |
Why?
| | Vital Capacity | 1 | 2002 | 249 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 125 | 0.050 |
Why?
| | Oxygen Consumption | 3 | 2012 | 568 | 0.050 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 103 | 0.050 |
Why?
| | Serum Response Factor | 1 | 2021 | 28 | 0.050 |
Why?
| | Microscopy, Atomic Force | 1 | 2021 | 111 | 0.050 |
Why?
| | Lymphocyte Count | 2 | 2011 | 131 | 0.040 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 49 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2016 | 712 | 0.040 |
Why?
| | Cardiac Output, Low | 1 | 2021 | 66 | 0.040 |
Why?
| | Endothelins | 1 | 2021 | 61 | 0.040 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 30 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 435 | 0.040 |
Why?
| | Mice, Inbred C57BL | 4 | 2014 | 4617 | 0.040 |
Why?
| | Aged, 80 and over | 3 | 2012 | 6296 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2021 | 123 | 0.040 |
Why?
| | Cytochromes c | 2 | 2010 | 60 | 0.040 |
Why?
| | Chemokine CXCL12 | 2 | 2010 | 74 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2006 | 2164 | 0.040 |
Why?
| | Cardiorespiratory Fitness | 1 | 2019 | 35 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 200 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 585 | 0.040 |
Why?
| | Disease Progression | 1 | 2006 | 2364 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2021 | 382 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 387 | 0.040 |
Why?
| | HIV Antibodies | 1 | 2019 | 49 | 0.040 |
Why?
| | Telomerase | 2 | 2011 | 203 | 0.040 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 368 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2021 | 542 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2020 | 181 | 0.040 |
Why?
| | Antioxidants | 1 | 2022 | 527 | 0.040 |
Why?
| | Electrocardiography | 1 | 2021 | 558 | 0.040 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2018 | 36 | 0.040 |
Why?
| | Outpatients | 1 | 2021 | 324 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2019 | 146 | 0.040 |
Why?
| | Freezing | 1 | 2018 | 83 | 0.040 |
Why?
| | Fasting | 2 | 2013 | 242 | 0.040 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 16 | 0.030 |
Why?
| | Cell Size | 1 | 2017 | 79 | 0.030 |
Why?
| | Galectin 3 | 1 | 2016 | 18 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2082 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2016 | 55 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1114 | 0.030 |
Why?
| | Genetic Markers | 1 | 2017 | 318 | 0.030 |
Why?
| | Electron Transport | 1 | 2016 | 108 | 0.030 |
Why?
| | Renin-Angiotensin System | 1 | 2017 | 72 | 0.030 |
Why?
| | Infusions, Intraosseous | 1 | 2016 | 20 | 0.030 |
Why?
| | Hot Temperature | 1 | 2018 | 298 | 0.030 |
Why?
| | Stem Cell Transplantation | 1 | 2017 | 144 | 0.030 |
Why?
| | Drug Discovery | 1 | 2016 | 122 | 0.030 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 170 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2581 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 287 | 0.030 |
Why?
| | Mutation | 1 | 2006 | 3313 | 0.030 |
Why?
| | Myogenic Regulatory Factors | 2 | 2006 | 47 | 0.030 |
Why?
| | MEF2 Transcription Factors | 2 | 2006 | 53 | 0.030 |
Why?
| | Cardiomegaly, Exercise-Induced | 1 | 2014 | 3 | 0.030 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2014 | 33 | 0.030 |
Why?
| | Caseins | 1 | 2014 | 18 | 0.030 |
Why?
| | Colorado | 2 | 2016 | 4061 | 0.030 |
Why?
| | Interleukin-18 | 2 | 2006 | 217 | 0.030 |
Why?
| | Consensus | 1 | 2016 | 533 | 0.030 |
Why?
| | Algorithms | 1 | 2021 | 1462 | 0.030 |
Why?
| | Cross-Over Studies | 2 | 2008 | 432 | 0.030 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 93 | 0.030 |
Why?
| | Heart Conduction System | 1 | 2014 | 81 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 152 | 0.030 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 170 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 442 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 116 | 0.030 |
Why?
| | Models, Cardiovascular | 1 | 2014 | 175 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 444 | 0.030 |
Why?
| | Genistein | 1 | 2012 | 11 | 0.030 |
Why?
| | Interleukin-1 | 1 | 2016 | 930 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 783 | 0.020 |
Why?
| | Ovariectomy | 1 | 2012 | 116 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 156 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2012 | 94 | 0.020 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2012 | 167 | 0.020 |
Why?
| | Cholinergic Agonists | 1 | 2011 | 6 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2012 | 195 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 345 | 0.020 |
Why?
| | Administration, Oral | 1 | 2013 | 719 | 0.020 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 37 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2012 | 180 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2006 | 1106 | 0.020 |
Why?
| | Cardiomyopathies | 1 | 2014 | 296 | 0.020 |
Why?
| | Waist Circumference | 1 | 2011 | 120 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 118 | 0.020 |
Why?
| | Anthropometry | 1 | 2011 | 182 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 168 | 0.020 |
Why?
| | Phenotype | 2 | 2011 | 2754 | 0.020 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.020 |
Why?
| | Staurosporine | 1 | 2010 | 20 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6189 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 70 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 191 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 288 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 324 | 0.020 |
Why?
| | Ultrasonography | 1 | 2012 | 632 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 394 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 932 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2244 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2008 | 47 | 0.020 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2008 | 40 | 0.020 |
Why?
| | Computational Biology | 1 | 2011 | 527 | 0.020 |
Why?
| | Arm | 1 | 2007 | 101 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2007 | 131 | 0.020 |
Why?
| | Probability | 1 | 2007 | 285 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2006 | 124 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2006 | 60 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2006 | 76 | 0.020 |
Why?
| | Thymidine | 1 | 2005 | 57 | 0.020 |
Why?
| | NFATC Transcription Factors | 1 | 2006 | 76 | 0.020 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2006 | 126 | 0.020 |
Why?
| | Caspases | 1 | 2006 | 236 | 0.010 |
Why?
| | Glycogen | 1 | 2004 | 50 | 0.010 |
Why?
| | Thrombosis | 1 | 2007 | 293 | 0.010 |
Why?
| | Calmodulin | 1 | 2004 | 70 | 0.010 |
Why?
| | Ventricular Myosins | 1 | 2003 | 33 | 0.010 |
Why?
| | Adenine | 1 | 2005 | 217 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 128 | 0.010 |
Why?
| | Cholesterol | 1 | 2005 | 365 | 0.010 |
Why?
| | Diastole | 1 | 2003 | 135 | 0.010 |
Why?
| | Sarcomeres | 1 | 2003 | 88 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2003 | 397 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2003 | 260 | 0.010 |
Why?
| | Muscarinic Antagonists | 1 | 2003 | 25 | 0.010 |
Why?
| | Physical Education and Training | 1 | 2003 | 62 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2003 | 324 | 0.010 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 603 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 85 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2003 | 150 | 0.010 |
Why?
| | Models, Animal | 1 | 2003 | 337 | 0.010 |
Why?
| | Lipoproteins | 1 | 2003 | 157 | 0.010 |
Why?
| | Mutation, Missense | 1 | 2003 | 293 | 0.010 |
Why?
| | Progesterone | 1 | 2003 | 230 | 0.010 |
Why?
| | Life Style | 1 | 2003 | 427 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 361 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1286 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 4880 | 0.010 |
Why?
| | Transcription Factors | 1 | 2004 | 1497 | 0.010 |
Why?
| | Insulin | 1 | 2005 | 2076 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2003 | 1068 | 0.010 |
Why?
|
|
Stauffer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|